Alzheimer's Biomarker Adoption And Global Rollout Will Fuel Future Opportunity

Published
25 Nov 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
JP¥4,523.08
3.0% overvalued intrinsic discount
14 Aug
JP¥4,661.00
Loading
1Y
-20.7%
7D
5.9%

Author's Valuation

JP¥4.5k

3.0% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 8.80%

Shared on23 Apr 25
Fair value Decreased 3.05%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 0.69%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 0.30%

AnalystConsensusTarget has increased revenue growth from 2.3% to 2.6%.

Shared on02 Apr 25
Fair value Increased 15%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 16%

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Increased 19%

AnalystConsensusTarget has decreased revenue growth from 5.4% to 3.4%.